Here we show that treatment of human glioma cell lines with the tyrosine kinase inhibitors imatinib and nilotinib produces a rapid and striking increase in tyrosine phosphorylation of p130Cas, FAK and PXN, key signalling molecules required for cell motility20, 24. Here, BCAR1 is linked to glioma.